This application is focused on capitalizing on our recent discovery that a carboxamido group (CONH2) can replace the phenolic OH of opioids and ameliorate the rapid clearance of opioids (e.g., duration of action increased from 2 to 15 hours) without compromising intrinsic affinity for opioid receptors or antinociception efficacy. Specifically, we will design, synthesize and characterize novel 8-carboxamido analogues of cyclazocine and ethylketocyclazocine (EKC) as potential anti-cocaine and anti- heroin medications. Cyclazocine is a k opioid agonist and a mu opioid antagonist and is currently in a clinical trial as a possible medication for cocaine abuse. Kappa agonists and mu antagonists decrease dopamine release in the nucleus acumens, a primary pathway involved in the reinforcing effects of drugs of abuse, and thus have the potential to treat drug abuse. EKC was shown to block cocaine self-administration in non-human primates. Therefore, derivatives of cyclazocine and EKC that do not have major side effects are potential medications for treating cocaine and heroin abuse in humans. We will also characterize novel carboxamido derivatives of other opioids (e.g., naltrindole, naltrexone) used as biochemical tools or for heroin abuse. ? ? Due to the uniqueness of this discovery, there is enormous potential to define a new SAR for opioids and we expect to identify new compounds having high affinity for opioid receptors. Taking advantage of computational techniques and our results with 8-aminocyclazocine analogues, we will probe an unexplored region of receptor space where an H-bond donor and hydrophobic group in the proper conformation are important for recognition. ? ? Based on the excellent preliminary pharmacokinetic and efficacy profile exhibited by these new carboxamides, we expect that the desired pharmacological profile will be attained by rational medicinal chemistry design and synthesis; an extensive pre-clinical work plan has been put in place. Radioligand binding, [35 S]GTP-gamma-S, and mouse antinociceptive assays will be used to characterize new targets pharmacologically.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA012180-06
Application #
6757177
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Shih, Ming L
Project Start
1999-09-01
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$315,398
Indirect Cost
Name
Rensselaer Polytechnic Institute
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
002430742
City
Troy
State
NY
Country
United States
Zip Code
12180
VanAlstine, Melissa A; Wentland, Mark P; Alvarez, Juan et al. (2013) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors. Bioorg Med Chem Lett 23:2128-33
Wentland, Mark P; Jo, Sunjin; Gargano, Joseph M et al. (2012) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC. Bioorg Med Chem Lett 22:7340-4
Wentland, Mark P; Lou, Rongliang; Lu, Qun et al. (2009) Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett 19:2289-94
Wentland, Mark P; Lou, Rongliang; Lu, Qun et al. (2009) Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett 19:203-8
Wentland, Mark P; Lu, Qun; Ganorkar, Rakesh et al. (2009) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine. Bioorg Med Chem Lett 19:365-8
Wentland, Mark P; Sun, Xufeng; Cohen, Dana J et al. (2008) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine. Bioorg Med Chem 16:5653-64
VanAlstine, Melissa A; Wentland, Mark P; Cohen, Dana J et al. (2007) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC. Bioorg Med Chem Lett 17:6516-20
Wentland, Mark P; VanAlstine, Melissa; Kucejko, Robert et al. (2006) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine. J Med Chem 49:5635-9
Wentland, Mark P; Sun, Xufeng; Bu, Yigong et al. (2005) Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Bioorg Med Chem Lett 15:2547-51
Wentland, Mark P; Lu, Qun; Lou, Rongliang et al. (2005) Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett 15:2107-10

Showing the most recent 10 out of 20 publications